AstraZeneca ($~AZN) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The CICERO study, officially titled “A Non-interventional, Prospective, Open-label, Observational Study Evaluating the Effectiveness and Safety of Acalabrutinib (Calquence®) in Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Direct Oral Anticoagulation (DOAC),” tracks real world outcomes for Calquence in CLL patients also using blood thinners. It focuses on safety and effectiveness, an area of high interest because many CLL patients are older and at higher clotting and bleeding risk.
The main treatment is acalabrutinib, marketed by AstraZeneca as Calquence, a targeted cancer drug used for CLL. The study also allows use with or without the antibody obinutuzumab and includes patients on common oral blood thinners like apixaban or rivaroxaban to see how these medicines work together in routine practice.
This is an observational, cohort study rather than a randomized trial, meaning doctors choose treatment and researchers then track outcomes. It is prospective and open label, so patients are followed forward in time with no blinding, and the main goal is to understand safety and everyday effectiveness, not to test Calquence against a control arm.
The study was first submitted on 19 August 2022, indicating planning and start-up around that time. The most recent update posted on 30 April 2026 shows the information has been refreshed and the status marked completed, signaling data collection is over and analysis or reporting should follow.
For investors, this update supports the long term story for Calquence in CLL, especially in older patients who often need blood thinners, and positive real world safety could reinforce AstraZeneca’s position against BTK rivals from AbbVie/J&J and others. While the study alone is unlikely to move AZN sharply in the near term, reassuring data could strengthen confidence in durable revenue, label support and physician uptake, especially if competitors face safety concerns.
The CICERO study is now completed and recently updated, and further details are available on the ClinicalTrials portal.
To learn more about ~AZN’s potential, visit the AstraZeneca drug pipeline page.